Porton Down, UK, 8 September 2008: GW Pharmaceuticals plc (GWP:AIM) announces positive results from a placebo-controlled "randomized withdrawal" study of Sativex® in patients with neuropathic pain due ...
the call, please dial (877) 407-8133 within the U.S., (201) 689-8040 from outside the U.S. or toll free from the U.K.: 0 800 756 3429. A replay of the call will be made available for a period of two ...
LONDON – GW Pharma plc delivered positive results in a UK Phase III postmarketing study of Sativex, which will provide ballast for the launch of the cannabis-based product as a treatment for ...
A Scientific American article about Sativex, a cannabis extract spray that the FDA may approve for treatment of cancer pain after clinical trials are completed in 2014 or so, assures us (citing ...
LONDON, Sept. 23, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced today that agreement for a revised mutually-acceptable reimbursement price for Sativex(R) has ...
LONDON, Dec. 13, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel ...
London (UK) and Paris (France), 14 January 2014 -Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical company, and GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW"), a ...
H1 pretax profit 3.1 mln stg vs loss 2.7 mln last year Revenue up 45 pct at 16.6 mln stg Shares up 10 percent (Adds details) May 17 (Reuters) - GW Pharmaceuticals rebounded to profit for the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results